Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC JUDAH FISHMAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1649317264
CMS profile
29467
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$8,000.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,000.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $8,000.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC JUDAH FISHMAN

NPI 1649317264 · CMS profile ID 29467

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC JUDAH FISHMAN, NPI 1649317264, CMS profile ID 29467. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARC JUDAH FISHMAN, NPI 1649317264, CMS profile ID 29467. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARC JUDAH FISHMAN, NPI 1649317264, CMS profile ID 29467, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $8,000.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $8,000.0004/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818239209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,791.29 12
PY2021 $8,000.00 1
PY2022 $9,480.67 2
PY2023 $5,500.00 1
PY2025 $14,575.11 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,375.00 1
PY2025 Principal investigator $298,135.39 276
PY2024 Recipient $818.58 1
PY2024 Principal investigator $65,369.26 148
PY2023 Principal investigator $134,098.95 2
PY2021 Principal investigator $96,512.16 9
PY2020 Principal investigator $105,402.16 20
PY2019 Principal investigator $63,619.77 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

149 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119604
Principal investigator 1 Indivior Inc. $474.50 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119606
Principal investigator 1 Indivior Inc. $474.50 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119608
Principal investigator 1 Indivior Inc. $474.50 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119610
Principal investigator 1 Indivior Inc. $474.50 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119612
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119614
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119616
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119618
Principal investigator 1 Indivior Inc. $474.50 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119624
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119626
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119628
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119630
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119632
Principal investigator 1 Indivior Inc. $214.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119634
Principal investigator 1 Indivior Inc. $891.00 12/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119636
Principal investigator 1 Indivior Inc. $2,500.00 12/13/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119352
Principal investigator 1 Indivior Inc. $474.50 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118976
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118978
Principal investigator 1 Indivior Inc. $474.50 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118980
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118982
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118984
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118986
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118988
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118990
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118992
Principal investigator 1 Indivior Inc. $214.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118994
Principal investigator 1 Indivior Inc. $474.20 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118996
Principal investigator 1 Indivior Inc. $891.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118998
Principal investigator 1 Indivior Inc. $891.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119000
Principal investigator 1 Indivior Inc. $1,460.00 11/20/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144119148
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118696
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118698
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118700
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118702
Principal investigator 1 Indivior Inc. $474.50 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118722
Principal investigator 1 Indivior Inc. $474.50 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118724
Principal investigator 1 Indivior Inc. $474.50 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118726
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118728
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118730
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118732
Principal investigator 1 Indivior Inc. $891.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118734
Principal investigator 1 Indivior Inc. $214.00 10/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118736
Principal investigator 1 Indivior Inc. $1,180.00 10/14/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118396
Principal investigator 1 Indivior Inc. $214.00 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118138
Principal investigator 1 Indivior Inc. $214.00 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118140
Principal investigator 1 Indivior Inc. $474.50 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118152
Principal investigator 1 Indivior Inc. $474.50 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118154
Principal investigator 1 Indivior Inc. $474.50 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118156
Principal investigator 1 Indivior Inc. $474.50 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118158
Principal investigator 1 Indivior Inc. $214.00 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118160
Principal investigator 1 Indivior Inc. $214.00 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118162
Principal investigator 1 Indivior Inc. $214.00 09/18/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144118164
Principal investigator 1 Indivior Inc. $2,798.62 09/10/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144117978
Principal investigator 1 Indivior Inc. $140.00 09/04/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117906
Principal investigator 1 Indivior Inc. $474.20 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117538
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117540
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117542
Principal investigator 1 Indivior Inc. $891.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117544
Principal investigator 1 Indivior Inc. $891.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117546
Principal investigator 1 Indivior Inc. $474.50 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117768
Principal investigator 1 Indivior Inc. $474.50 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117770
Principal investigator 1 Indivior Inc. $474.50 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117772
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117774
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117776
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117778
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117780
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117782
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117816
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117818
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117820
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117822
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117824
Principal investigator 1 Indivior Inc. $214.00 08/23/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117826
Principal investigator 1 Indivior Inc. $2,739.94 08/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144117532
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117200
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117202
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117204
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117206
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117208
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117210
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117212
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117214
Principal investigator 1 Indivior Inc. $214.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117216
Principal investigator 1 Indivior Inc. $474.20 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117218
Principal investigator 1 Indivior Inc. $474.20 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117220
Principal investigator 1 Indivior Inc. $474.20 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117222
Principal investigator 1 Indivior Inc. $474.20 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117224
Principal investigator 1 Indivior Inc. $891.00 07/22/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144117226
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116893
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116895
Principal investigator 1 Indivior Inc. $474.20 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116897
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116899
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116901
Principal investigator 1 Indivior Inc. $474.20 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116903
Principal investigator 1 Indivior Inc. $474.20 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116905
Principal investigator 1 Indivior Inc. $474.20 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116907
Principal investigator 1 Indivior Inc. $474.20 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116912
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116914
Principal investigator 1 Indivior Inc. $474.20 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116916
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116918
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116920
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116922
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116924
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116926
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116928
Principal investigator 1 Indivior Inc. $891.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116930
Principal investigator 1 Indivior Inc. $214.00 06/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116932
Recipient Indivior Inc. $818.58 05/31/2024 Covered Recipient Physician A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144114797
Principal investigator 1 Indivior Inc. $214.00 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116685
Principal investigator 1 Indivior Inc. $214.00 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116687
Principal investigator 1 Indivior Inc. $214.00 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116689
Principal investigator 1 Indivior Inc. $214.00 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116691
Principal investigator 1 Indivior Inc. $474.20 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116713
Principal investigator 1 Indivior Inc. $474.20 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116715
Principal investigator 1 Indivior Inc. $474.20 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116717
Principal investigator 1 Indivior Inc. $214.00 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116719
Principal investigator 1 Indivior Inc. $474.20 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116721
Principal investigator 1 Indivior Inc. $214.00 05/17/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116723
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116427
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116429
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116431
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116433
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116435
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116437
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116439
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116441
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116443
Principal investigator 1 Indivior Inc. $214.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116445
Principal investigator 1 Indivior Inc. $891.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116447
Principal investigator 1 Indivior Inc. $891.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116449
Principal investigator 1 Indivior Inc. $891.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116451
Principal investigator 1 Indivior Inc. $891.00 04/24/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116453
Principal investigator 1 Indivior Inc. $891.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116025
Principal investigator 1 Indivior Inc. $891.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116027
Principal investigator 1 Indivior Inc. $214.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116137
Principal investigator 1 Indivior Inc. $214.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116139
Principal investigator 1 Indivior Inc. $214.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116141
Principal investigator 1 Indivior Inc. $214.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116143
Principal investigator 1 Indivior Inc. $214.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116145
Principal investigator 1 Indivior Inc. $214.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116147
Principal investigator 1 Indivior Inc. $891.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116149
Principal investigator 1 Indivior Inc. $891.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116151
Principal investigator 1 Indivior Inc. $891.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116153
Principal investigator 1 Indivior Inc. $891.00 03/25/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144116155
Principal investigator 1 Indivior Inc. $891.00 02/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144115775
Principal investigator 1 Indivior Inc. $891.00 02/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144115777
Principal investigator 1 Indivior Inc. $891.00 02/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144115779
Principal investigator 1 Indivior Inc. $891.00 02/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144115781
Principal investigator 1 Indivior Inc. $891.00 02/21/2024 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1144115783